Tissue repair in mammals involves the integrated actions of growth factors and matrix molecules that orchestrate cell-cell interactions[@R9]--[@R11]. Fibrosis of diverse tissues occurs when this process is dysregulated by impaired re-epithelialization in association with myofibroblast activation[@R9],[@R11]. Myofibroblast differentiation and activation are critically dependent on TGF-β1, matrix signaling, and biomechanical tension[@R12]--[@R14]. We have previously reported that myofibroblast differentiation by TGF-β1 is associated with the activation of a flavoenzyme that generates extracellular H~2~O~2~[@R15]--[@R17]. NOX4 has been implicated in the differentiation of cardiac fibroblasts to myofibroblasts[@R18]. However, physiological and pathophysiological roles for NOX4 in tissue repair and fibrogenesis are not well defined.

We identified *NOX4* as one of the most highly induced genes by whole-genome Affymetrix analysis in human fetal lung mesenchymal cells (hFLMCs) stimulated with TGF-β1; other members of the NOX gene family were not affected at the mRNA level ([Fig. 1a](#F1){ref-type="fig"}). The upregulation of *NOX4* mRNA by TGF-β1 was confirmed by RT-PCR ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}) and NOX4 protein expression was induced in a time-dependent manner ([Fig. 1b](#F1){ref-type="fig"} and [Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}). To define the specific role of *NOX4*, an RNA interference (RNAi) approach utilizing small interfering RNA (siRNA) targeting *NOX4* was employed. Two of four siRNA duplexes, duplex 3 and duplex 4, efficiently blocked NOX4 induction by TGF-β1 ([Supplementary Fig. 1c](#SD1){ref-type="supplementary-material"}). The *NOX4* siRNA duplex 4 was utilized in subsequent *in vitro* studies designed to examine the role for NOX4 in myofibroblast differentiation and activation. RNAi-mediated knockdown of NOX4 significantly inhibited TGF-β1-induced H~2~O~2~ production in hFLMCs ([Fig. 1c](#F1){ref-type="fig"}), implicating NOX4 as the primary enzymatic source of extracellular H~2~O~2~ generation by TGF-β1-differentiated myofibroblasts.

TGF-β1 signals via two heterodimeric transmembrane receptors, the type II and type I (ALK5) receptors. To define upstream mechanisms of TGF-β1-induced NOX4 induction and H~2~O~2~ generation in myofibroblasts, we tested the effect of pharmacologic inhibitors of ALK5 and canonical MAPK pathways. Of these, only ALK5 inhibition attenuated the induction of H~2~O~2~ production by hFLMCs ([Fig. 1d](#F1){ref-type="fig"}). The ALK5 receptor is known to activate SMAD2 and SMAD3; however, pro-fibrotic effects TGF-β1/ALK5 signaling have been largely attributed to SMAD3 signaling[@R19]. We employed an RNAi strategy to determine if SMAD3 is required for NOX4 induction and H~2~O~2~ generation in hFLMCs; SMAD3 siRNA knockdown inhibited TGF-β1-induced NOX4 inducibility ([Fig. 1e](#F1){ref-type="fig"}) and H~2~O~2~ production ([Fig. 1f](#F1){ref-type="fig"}). Similarly, a requirement for SMAD3 signaling in TGF-β1-induced NOX4 expression was observed in primary mesenchymal cells isolated from lungs of human subjects with IPF ([Supplementary Fig. 1d](#SD1){ref-type="supplementary-material"}), a chronic fibrosing and ultimately fatal lung disease. These data support a role for TGF-β1 signaling via ALK5/SMAD3 in the induction and activation of NOX4 in myofibroblasts.

Myofibroblasts contribute to the tissue repair by secreting ECM proteins and remodeling/contracting the ECM[@R9],[@R11]. We utilized a 3D-collagen matrix cell culture system to determine if fibronectin synthesis and contractile functions of myofibroblasts are regulated by NOX4 activation and extracellular H~2~O~2~ generation. The upregulation of α-smooth muscle actin (α-SMA), a cytoskeletal component of contractile actin stress fibers, and fibronectin synthesis induced by TGF-β1 were inhibited by addition of catalase ([Fig. 1g](#F1){ref-type="fig"}), an enzyme which reduces H~2~O~2~ to H~2~O, indicating a role for H~2~O~2~ in mediating these effects. Similar to the effects of catalase, endogenous suppression of NOX4 by siRNA knockdown inhibited TGF-β1-induced expression of α-SMA, fibronectin, and procollagen-I ([Fig. 1h](#F1){ref-type="fig"}). Next, we studied whether NOX4-dependent H~2~O~2~ production by myofibroblasts is required for their capacity to contract 3D-collagen gels. Both the exogenous introduction of catalase and RNAi-mediated knockdown of NOX4 inhibited TGF-β1-induced collagen gel contractility ([Fig. 1i,j](#F1){ref-type="fig"}). Together, these studies indicate a critical role for NOX4-dependent H~2~O~2~ in conferring synthetic and contractile properties to myofibroblasts that differentiate under the influence of TGF-β1.

To investigate a potential role for NOX4 in a human fibrotic disease, lung tissue sections from IPF were examined. NOX4 is highly expressed in myofibroblastic foci of the remodeled IPF lung, as determined by immunohistochemical (IHC) staining ([Fig. 2a](#F2){ref-type="fig"}). Additionally, lung mesenchymal cells isolated from explants of IPF lung tissue (IPF-MCs) were studied *ex vivo*. Similar to our findings in hFLMCs, NOX4 was found to be induced and necessary for TGF-β1-stimulated H~2~O~2~ production ([Fig. 2b](#F2){ref-type="fig"}); NOX4 was also required for the induction of α-SMA and fibronectin mRNA ([Fig. 2c](#F2){ref-type="fig"} e) and protein expression ([Fig. 2f](#F2){ref-type="fig"}) by TGF-β1. Differentiated myofibroblasts are known to secrete higher amounts of extracellular collagen. We evaluated the role of NOX4 on collagen secretion by IPF-MCs. Constitutive and TGF-β1-induced secretion of soluble collagen by IPF-MCs were inhibited by siRNA-mediated knockdown of NOX4 ([Fig. 2g](#F2){ref-type="fig"}). We examined the role of NOX4 in IPF-MC proliferation in response to serum; siRNA-mediated knockdown of NOX4 inhibited serum-stimulated proliferation of IPF-MCs ([Fig. 2h,i](#F2){ref-type="fig"}). These data support a critical role for NOX4 in myofibroblast differentiation and proliferation of human IPF-MCs.

To define the *in vivo* role of NOX4 in the reparative response to injury of the mammalian lung, a murine model of acute lung injury was employed. In this model, direct airway instillation of the chemotherapeutic drug, bleomycin, causes epithelial injury with subsequent mesenchymal cell activation and fibrosis. Several key features of fibrotic reactions in mammalian tissues, including TGF-β1 upregulation/activation and myofibroblast differentiation/activation are recapitulated in this animal model[@R20]. We first determined whether NOX4 expression is induced during the fibrogenic phase of bleomycin-induced lung injury. NOX4 was induced in a time-dependent manner, increasing from day 7 up to day 28 ([Fig. 3a](#F3){ref-type="fig"}), supporting a temporal relationship between NOX4 expression, myofibroblast activation and fibrosis following lung injury. In contrast, expression of the NOX2 isoform, which is predominantly expressed in phagocytic cells, was increased on day 7 and returned to baseline levels at later time-points when inflammatory responses have subsided ([Fig. 3a](#F3){ref-type="fig"}).

The effects of targeted suppression of NOX4 induction employing an *in vivo* RNAi approach in two different animal models of lung injury/fibrosis were examined. We first confirmed that the murine siRNA homologous to the human *NOX4* siRNA duplex 4 ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}) efficiently knocked down NOX4 in cultured primary murine mesenchymal cells ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). In the first animal model, *NOX4* siRNA or nontargeting control siRNA was instilled directly down the trachea of mice at the time of bleomycin injury (day 0), and tissues were analyzed at day 14 or 21. *NOX4* siRNA was effective in inhibiting NOX4 induction in injured lung tissue at 21 days as determined by Western immunoblotting ([Fig. 3b](#F3){ref-type="fig"}), and at day 14 as determined by IHC analysis ([Fig. 3c](#F3){ref-type="fig"}). IHC analysis confirmed NOX4 expression localized to fibrotic foci surrounding remodeled alveolar structures on day 14 post-lung injury ([Fig. 3c](#F3){ref-type="fig"}). NOX4 knockdown mediated a marked anti-fibrotic effect as determined by histopathology, trichrome staining for collagen, IHC analysis of α-SMA ([Fig. 3c](#F3){ref-type="fig"}), and by biochemical analyses of hydroxyproline content ([Fig. 3d](#F3){ref-type="fig"}) and acid-soluble collagen ([Fig. 3e](#F3){ref-type="fig"}) in whole lung homogenates.

Pharmacological approaches that specifically target fibrogenic processes are currently lacking. To determine if pharmacologic blockade of NOX/flavoenzyme activity during the post-injury reparative phase protects against fibrogenic tissue responses, the flavoenzyme inhibitor, diphenyleneiodonium chloride (DPI), was employed. DPI, which blocks NOX4 activity in myofibroblasts at a relatively low IC~50~ (\<0.5 μM; data not shown), was administered by daily intra-peritoneal injection on days 8 to 21 following bleomycin lung injury. We delayed DPI administration until day 8 to minimize effects of the drug on inflammatory responses that typically subside following the first week bleomycin lung injury in mice[@R21],[@R22]. Mice receiving DPI demonstrated significant protection from fibrosis, as measured by acid-soluble collagen in whole lung ([Fig. 3f](#F3){ref-type="fig"}); this is associated with reduced fibrosis as determined by histopathology, Masson's trichrome staining for collagen, as well as reduced expression of NOX4 and α-SMA-expressing myofibroblasts ([Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}).

We also employed a hapten (fluorescein isothiocyanate; FITC)-driven lung injury/fibrosis murine model to test the role of NOX4 in fibrogenesis[@R23]. In this model, *NOX4* siRNA was instilled directly down the trachea of mice at the time of FITC injury (day 0), and tissues were analyzed on day 14 or 21. This RNAi approach was effective in inhibiting NOX4 induction at day 21 post-lung injury ([Fig. 4a](#F4){ref-type="fig"}). The fibrotic response surrounding airways where FITC is deposited was found to be markedly attenuated in mice receiving *NOX4* siRNA versus nontargeting siRNA, as determined by histopathology and trichrome staining for collagen ([Fig. 4b](#F4){ref-type="fig"}); this was confirmed by analyzing whole lung homogenates for acid-soluble collagen by Sircol assay ([Fig. 4c](#F4){ref-type="fig"}) and acid-insoluble collagen by hydroxyproline assay ([Fig. 4d](#F4){ref-type="fig"}).

In this study, we demonstrate a functional role for *NOX4* in myofibroblast differentiation and activation *ex vivo* and in fibrogenic responses to lung injury *in vivo*. The pro-fibrogenic mediator, TGF-β1, specifically induces mRNA/protein expression and enzymatic activation of the *NOX4* isoform in differentiated myofibroblasts. NOX4-dependent H~2~O~2~ generation is required for myofibroblast differentiation, synthesis of ECM proteins, and contractility mediated by TGF-β1. NOX4 is expressed in myofibroblastic foci of remodeled IPF lung tissue, supporting a role for this NOX isoform in the induction and activation of myofibroblasts in this human pulmonary disorder. In two different murine models of pulmonary fibrosis, genetic or pharmacologic strategies targeting NOX4 induction or activity protects against fibrosis. We utilized an RNAi strategy to suppress NOX4 expression by administering *NOX4* siRNA at the time of bleomycin or FITC injury. It is likely that the disruption of the airway-alveolar epithelial barrier immediately following bleomycin/FITC injury facilitated the transduction of siRNA to epithelial or mesenchymal precursor cells that prevented their differentiation into activated myofibroblasts, thus protecting from lung fibrosis.

These are the first studies, to our knowledge, to definitively implicate a specific NOX isoform in tissue repair functions and fibrogenesis. We speculate that *NOX4* may have been selected during metazoan evolution to execute tissue repair functions critical for the survival of more complex multicellular eukaryotes[@R24]. In support of this notion, *NOX4* is almost exclusively expressed in chordates[@R25]. Furthermore, NOX4 activation in myofibroblasts and tissue fibrogenesis may represent yet another example of antagonistic pleiotropy, whereby genes that confer a survival advantage during early reproductive life mediate potential harmful effects in later life[@R26]. Fibrosis is typically a complication of failed tissue regeneration and ineffective epithelial repair in diverse organ systems, often with an age-dependent increase in incidence[@R27]. Fibrosis in mammalian tissues is perhaps best viewed as an initial adaptive response executed by mesenchymal cells to restore tissue barrier function while secreting a provisional matrix to facilitate re-epithelialization; however, persistent mesenchymal activation and failed re-epithelialization results in unrestrained and progressive fibrosis. Targeting NOX4 may prove to be an effective therapeutic strategy for an otherwise treatment-unresponsive and ultimately fatal group of human fibrotic disorders.

METHODS {#S1}
=======

Reagents {#S2}
--------

We purchased porcine platelet-derived TGF-β1 was obtained from R&D Systems, Minneapolis, MN; protease inhibitor cocktail set III from Calbiochem, San Diego, CA. We purchased monoclonal antibodies to fibronectin (clone IST-4) and β-actin (clone AC-15) from Sigma, St. Louis, MO; monoclonal antibody to α-SMA (clone 1A4) from Dako, Carpinteria, CA; antibody to SMAD3 from Cell Signaling Technology, Danvers, MA; antibody to procollagen-I from Cederlane laboratories, Hornby, Ontario, Canada; and rabbit polyclonal antibody to GAPDH antibody from Abcam Inc., Cambridge, MA. We purchased all other reagents from Sigma unless otherwise specified.

Cell culture {#S3}
------------

We obtained human fetal lung mesenchymal cells (hFLMCs; IMR-90 cells) from Coriell Cell Repositories, Institute for Medical Research, Camden, NJ. We isolated primary mesenchymal cells from the lungs of C57BL/6 mice as previously described[@R22]. We obtained primary lung mesenchymal cells isolated by explant cultures from lung tissues of human subjects with IPF (IPF-MCs) under an approved protocol by the Institutional Review Board at the University of Michigan. Informed consent was obtained from all individuals enrolled in the Lung Tissue Research Consortium of the National Institutes of Health. We cultured all mesenchymal cells in DMEM (Life Technologies, Inc.) supplemented with 10% fetal calf serum (Hyclone Laboratories, Logan, UT), 100 U/ml penicillin, 100 μg/ml streptomycin, and 1.25 μg/ml amphotericin B, and incubated cells at 37°C in 5% CO~2~, 95% air.

3D-collagen gels {#S4}
----------------

We reconstituted collagen gels by mixing 1 part of 3 mg/ml neutralized rat tail collagen type 1 and two parts of cell suspension in serum-free media. We seeded cell suspensions at a density of 200,000 cells per ml into 24-well tissue culture plates and allowed the gels to polymerize at 37°C for 1 h before adding 1 ml of media. We incubated gels overnight prior to treatments, and gently detached the edge of the gels from the walls of the well using a sterile spatula. We photographed images of gels and measured gel area using ImageJ (NIH) software.

Murine model of bleomycin/FITC lung injury {#S5}
------------------------------------------

We anesthetized C57BL/6J mice (6--8 weeks of age; Jackson Laboratories, Bar Harbor, ME) with intraperitoneal injection of ketamine and xylazine. We administered intra-tracheal bleomycin (0.025 U) or FITC (4.67 mg/ml suspension in PBS) to induce lung injury as previously described[@R22]. The University of Michigan Committee on the Use and Care of Animals approved the animal protocols.

RNA interference {#S6}
----------------

For *in vitro* RNAi, we transfected cells with single duplexes targeting *NOX4* or nontargeting control siRNA (100 nM) using Lipofectamine-2000 reagent. For *in vivo* RNAi studies, we administered *NOX4* siRNA or control nontargeting siRNA (Dharmacon Inc.) at a dose of \~50 μg per mouse by intratracheal injection with bleomycin, FITC, or saline, in a total volume of 50 μl using a 26-gauge needle.

Real-time PCR {#S7}
-------------

We isolated total RNA from cells using the RNeasy^®^ Mini Kit (Qiagen) and reverse transcribed using M-MLV RT First-Strand Synthesis (Invitrogen) as per manufacturers' protocols. We performed real-time PCR reactions for each cDNA sample in triplicate using SYBR^®^ Green PCR Master Mix (Applied Biosystems) and gene specific primer pairs for α-actin, *NOX4*, *α-SMA*, and fibronectin ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). We carried out reactions for 40 cycles (95°C for 15 sec, 60°C for 1 min) in a 7300 Real Time PCR System (Applied Biosystems, Foster City, CA). We expressed semi-quantitative real-time PCR data for each target gene as 2^−ΔΔCt^ Relative Quantitation (RQ) versus endogenous β-actin, with error bars representing the standard error of the mean for triplicate reactions. We performed a 2-way analysis of variance (ANOVA) with Bonferroni post-test on grouped data.

Gene microarray analyses {#S8}
------------------------

We hybridized RNA isolates on microarray Affymetrix U133A chips with 22976 probe-pairs and the University of Michigan Microarray Core facility performed the statistical analyses.

Western immunoblotting {#S9}
----------------------

We prepared cell lysates in RIPA buffer, subjected them to SDS-PAGE under reducing conditions and performed western immunoblotting as previously described[@R28].

Measurement of H~2~O~2~ production {#S10}
----------------------------------

We assayed extracellular H~2~O~2~ release from cultured cells as previously described[@R15].

BrdU incorporation assay and coulter counting {#S11}
---------------------------------------------

We serum-starved cells cultured in 96-well plates for 24 h followed by BrdU pulse in media with/without 10% serum for 24 hours. We measured BrdU incorporation using a kit from Calbiochem (Cat \#QIA58). We measured cell counts using a coulter counter (model ZM, Coulter Electronic, Hialeah, FL).

Sircol assay for collagen {#S12}
-------------------------

We assessed acid-soluble collagen in cell culture supernatants or whole lung homogenates using the Sircol assay as previously described[@R22].

Hydroxyproline content of whole lung {#S13}
------------------------------------

We homogenized murine whole lungs in PBS, then acidified (by adding an equal volume of 12 N HCl), hydrolyzed (by heating at 120°C for 24 h), and processed samples for hydroxyline measurements as previously described[@R29].

Lung histology and immunohistochemical staining {#S14}
-----------------------------------------------

We processed paraffin embedded tissue sections for lung histology and immunohistochemical staining as previously described[@R22].

Statistical Analysis {#S15}
--------------------

We expressed data from various groups as mean ± S.E.M. We made statistical comparisons using the Student's *t* test for unpaired samples. We analyzed Affymetrix data using two-sample *t* test of log data.

Supplementary Material {#S16}
======================
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![Identification of NOX4 as the enzymatic source of extracellular H~2~O~2~ production by myofibroblasts and its role in mediating myofibroblast differentiation and contractility\
(**a**) RNA was isolated from human fetal lung mesenchymal cells (hFLMCs) treated with/without TGF-β1 (2 ng/ml) for 18 h and analyzed by Affymetrix (U133A) microarray for members of the NOX/DUOX gene family. Values represent mean ± S.D., *n* = 3 per group. ^\*^*P* \< 0.001 compared to control. ND indicates "not detected" (below threshold). (**b**) hFLMCs were treated with/without TGF-β1 (2 ng/ml) for the times indicated and cell lysates subjected to SDS-PAGE and Western immunoblotting for NOX4 and GAPDH. (**c**) Effect of *NOX4* siRNA (duplex 4) on extracellular release of H~2~O~2~ by hFLMCs treated with/without TGF-β1 (2 ng/ml for 16 h). (**d**) hFLMCs were pretreated with pharmacologic inhibitors against ALK5 receptor kinase (SB431542; 1 μM), MEK (PD98059; 20 μM), p38 MAPK (SB203580; 6 μM), JNK (SP600125; 100 nM), and then stimulated with TGF-β1 (2 ng/ml × 16 h) prior to measurement of extracellular H~2~O~2~ release. (**e**) Effect of SMAD3 siRNA knockdown on TGF-β1-induced NOX4 expression in hFLMCs, as determined by Western immunoblotting. (**f**) Effect of siRNA-mediated knockdown of SMAD3 on extracellular H~2~O~2~ production stimulated by TGF-β1 (2 ng/ml × 16 h) in hFLMCs. (**g**) hFLMCs in 3-D collagen matrix were stimulated with/without TGF- β1 (2 ng/ml × 16 h) in the presence/absence of catalase (750 U/ml) and effects on α-smooth muscle actin (α-SMA), fibronectin, and β-actin were determined by Western immunoblotting. (**h**) Effect of siRNA-mediated silencing of NOX4 in 3D-collagen matrix-embedded hFLMCs on cellular expression of α-SMA, fibronectin, and procollagen-1 treated with/without TGF-β1 (2.5 ng/ml × 72 h), as determined by Western immunoblotting. (**i,j**) Effect of exogenous catalase (750 U/ml) (**i**), and siRNA-mediated NOX4 silencing (**j**) on TGF-β1-induced contractility in 3D-collagen matrices. Values represent mean ± S.E.M.; *n* = 4. ^\*^*P* \< 0.001 compared to controls.](nihms125271f1){#F1}

![NOX4 is expressed in lungs of human subjects with idiopathic pulmonary fibrosis (IPF) and mediates H~2~O~2~ production, myofibroblast differentiation, and serum-stimulated proliferation of IPF-derived mesenchymal cells\
(**a**) Immunohistochemical staining demonstrating expression of NOX4 in myofibroblastic foci in lungs of a representative human subject with IPF. Length bar = 100 μm. (**b--i**) Mesenchymal cells isolated from IPF lung tissues (IPF-MCs) by explant tissue culture and analyzed at passage 2--5. (**b**) IPF-MCs were transfected with nontargeting (control) siRNA or *NOX4* siRNA and treated with/without TGF-β1 (2 ng/ml) for 16 h and analyzed for NOX4 protein (inset) and extracellular H~2~O~2~ production. (**c--f**) The effect of siRNA knockdown of NOX4 in IPF-MCs with/without TGF-β1 (2 ng/ml) on the expression of α-SMA mRNA (**c**) and protein (**f**); fibronectin mRNA (**d**) and protein (**f**); and *NOX4* mRNA (**e**) and protein (**f**), a**s** determined by real-time PCR (at 24 h) and Western immunoblotting (at 48 h). (**g**) Control (nontargeting) and *NOX4* siRNA transfected IPF-MCs were treated with/without TGF-β1 (2 ng/ml) for 48 h and conditioned culture media was collected and analyzed for acid-soluble collagen using the Sircol assay. (**h,i**) The effect of siRNA knockdown of NOX4 on proliferation of IPF-MCs treated with/without serum was determined at 24 h by BrdU incorporation assay (**h**) and at 48 h by assessment of cell numbers using a coulter counter (**i**). Values represent mean ± S.E.M.; *n* = 3--5. ^\*^*P* \< 0.001 compared to control (without TGF-β1 or serum) and nontargeting siRNA.](nihms125271f2){#F2}

![NOX4 is induced during the fibrogenic phase of bleomycin-induced lung injury in mice and inhibition of NOX4 expression/activity attenuates pulmonary fibrosis\
(**a**) C57BL/6 mice were subjected to acute lung injury by airway (intra-tracheal) administration of bleomycin or saline/control on day 0. Following bleomycin injury, mice were euthanized at the indicated time intervals, whole lungs were harvested, and tissue homogenates analyzed by SDS-PAGE and Western immunoblotting for NOX4, NOX2, and β-actin. (**b--e**) *NOX4* siRNA or a nontargeting control siRNA was instilled directly down the trachea of mice at the time of bleomycin injury (day 0), and lungs were analyzed on day 14 or 21. (**b**) NOX4 expression on day 21 was determined by Western immunoblotting of whole lung homogenates. (**c**) Fibrosis was assessed on day 14 by H & E staining and Masson's trichrome blue staining for collagen (top panels); NOX4 and α-SMA expression were assessed by immunohistochemical (IHC) analysis (bottom panels); length bar = 100 μm. (**d,e**) Whole lung homogenates were analyzed on day 21 for hydroxyproline content (**d**), and on day 14 for acid-soluble collagen using the Sircol assay (**e**). Values represent mean± S.E.M.; *n* = 4--6; ^\*^*P* \< 0.01 compared to all other groups. (**f**) C57BL/6 mice were administered intra-tracheal (IT) bleomycin on day 0. Diphenyleneiodonium (DPI; 1.6 mg/kg) or vehicle control was administered by daily intraperitoneal (IP) injections starting on day 7 for 14 days. Whole lung homogenates were analyzed for acid-soluble collagen using the Sircol assay on day 21. Values represent mean ± S.E.M.; *n* = 6; \**P* \< 0.05 compared to saline control.](nihms125271f3){#F3}

![RNAi-mediated knockdown of NOX4 attenuates fibrosis in mice subjected to fluorescein isothiocyanate-induced lung injury\
C57BL/6 mice were administered intra-tracheal fluorescein isothiocyanate (FITC) or saline/control on day 0 with nontargeting control siRNA or *NOX4* siRNA and lung tissues were analyzed on day 14 or 21. (**a**) NOX4 expression on day 21 was determined by Western immunoblotting of whole lung homogenates. (**b**) Fibrosis was assessed by H & E staining and Masson's trichrome blue staining for collagen; length bar = 100 μm. (**c,d**) Whole lung homogenates were analyzed on day 14 for acid-soluble collagen using the Sircol assay (**c**), and on day 21 for hydroxyproline content (**d**). Values represent mean± S.E.M.; *n* = 4--6; ^\*^*P* \< 0.01 compared to saline, nontargeting (control) siRNA.](nihms125271f4){#F4}
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